2018
Kappa opioid receptor binding in major depression: A pilot study
Miller JM, Zanderigo F, Purushothaman PD, DeLorenzo C, Rubin‐Falcone H, Ogden RT, Keilp J, Oquendo MA, Nabulsi N, Huang YH, Parsey RV, Carson RE, Mann JJ. Kappa opioid receptor binding in major depression: A pilot study. Synapse 2018, 72: e22042. PMID: 29935119, PMCID: PMC7599086, DOI: 10.1002/syn.22042.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsMajor depressive disorderPositron emission tomographyHealthy volunteersRecent life stressKOR bindingLife stressKappa-opioid receptor bindingCurrent major depressive disorderPilot studyVoxel-wise contrastsWhole-brain voxel-wise analysisOpioid receptor bindingSubstance use disordersCo-occurring moodSalivary cortisol levelsVoxel-wise analysisTrier Social Stress TestCortisol areaRaphe nucleusOpioid receptorsPsychotic featuresDepressive disorderMajor depressionPathological response
2016
First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430
Naganawa M, Waterhouse RN, Nabulsi N, Lin SF, Labaree D, Ropchan J, Tarabar S, DeMartinis N, Ogden A, Banerjee A, Huang Y, Carson RE. First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430. Journal Of Nuclear Medicine 2016, 57: 1388-1395. PMID: 27103022, PMCID: PMC5093918, DOI: 10.2967/jnumed.115.166850.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAzabicyclo CompoundsAzetidinesBrainComputer SimulationCyclic Nucleotide Phosphodiesterases, Type 2Feasibility StudiesFemaleHumansIsotope LabelingMacaca mulattaMaleMetabolic Clearance RateModels, BiologicalMolecular ImagingOrgan SpecificityPilot ProjectsPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsSensitivity and SpecificityTissue DistributionConceptsTest-retest variabilityHuman studiesPET ligandWhite matterNeocortical regionsMultilinear analysis 1MSv/MBqHealthy male subjectsDetectable pharmacologic effectsAppropriate tracer kinetic modelsTest-retest protocolAdverse eventsBrain uptakePharmacologic effectsRegional time-activity curvesTarget doseTime-activity curvesTracer uptakeMale subjectsWhole brainBrain regionsEffective doseCritical organsPET radiotracersNonhuman primates